Opaleye Management Inc. Acquires 222,146 Shares of 4D Molecular Therapeutics, Inc. $FDMT

Opaleye Management Inc. grew its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 197.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 334,437 shares of the company’s stock after purchasing an additional 222,146 shares during the quarter. Opaleye Management Inc.’s holdings in 4D Molecular Therapeutics were worth $4,448,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Dynamic Technology Lab Private Ltd bought a new stake in 4D Molecular Therapeutics in the first quarter valued at about $39,000. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics in the third quarter valued at about $41,000. AQR Capital Management LLC bought a new position in 4D Molecular Therapeutics during the first quarter worth about $46,000. Daiwa Securities Group Inc. boosted its holdings in 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after buying an additional 6,186 shares during the last quarter. Finally, Rangeley Capital LLC acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth about $48,000. 99.27% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at $103,404. This trade represents a 53.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $10.05, for a total transaction of $124,770.75. Following the completion of the sale, the insider owned 871,737 shares in the company, valued at $8,760,956.85. This trade represents a 1.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 199,158 shares of company stock worth $2,229,161. 7.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on FDMT. B. Riley Financial reaffirmed a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Chardan Capital upgraded shares of 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $32.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.62.

4D Molecular Therapeutics Price Performance

FDMT stock opened at $13.49 on Friday. The stock has a 50-day moving average price of $12.64 and a two-hundred day moving average price of $10.67. 4D Molecular Therapeutics, Inc. has a 1 year low of $6.47 and a 1 year high of $16.93. The stock has a market cap of $745.19 million, a PE ratio of -5.13 and a beta of 2.74. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). The firm had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. Equities analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.